Agilent Technologies has announced efforts to accelerate Stemina Biomarker Discovery's metobolomic research for the discovery of biomarkers, for use in drug screening and drug development.
Agilent is providing a 1290 Infinity UHPLC system to separate stem-cellular metabolites, coupled to a 6530 Accurate Mass quadrupole time-of-flight mass spectrometer (Q-TOF MS) to identify those metabolites.
Agilent also is providing Mass Profiler Professional software to help Stemina researchers interpret the complex data generated by metabolomics experiments.
'We are pleased to broaden our relationship with Agilent to advance our scientific platform and our discovery of important small molecules involved in developmental toxicity and autism,' said Beth Donley, Stemina chief executive officer.
'The Mass Profiler Professional software provides the crucial ability to visualise biological pathways from the massive and complex data sets generated by metabolomics studies,' said Gustavo Salem, Agilent vice president and general manager, Biological Systems Division.
